Exercise for Cancer Therapy-Induced Cardiotoxicity

This online activity will discuss the pathophysiology, risk factors, and evidence for exercise in the setting of cancer therapy-induced cardiotoxicity, with an emphasis on practical applications for AEPs working with cancer survivors at risk of cardiotoxicity.
 
Improved cancer treatment is resulting in a rapidly growing population of cancer survivors, which now exceeds 1-million individuals in Australia alone. However, increases in cancer survival have unmasked the cardiovascular consequences of cancer treatment, with cardiovascular disease (CVD) rivalling cancer as the major cause of premature death for survivors of solid and hematologic cancer. The cardiovascular damage (termed cardiotoxicity) caused by several common and emerging cancer treatments is a key factor underlying this shift, by increasing the risk of developing cardiac dysfunction, heart failure (HF), coronary artery disease and arrhythmias. This cardiovascular injury also results in marked reductions in cardiorespiratory fitness, functional limitations, and as a result, reduced quality of life.
 
Given the proven benefits of exercise for cardiovascular health and function in individuals living with or at risk for cardiovascular disease, there is growing interest in the role of exercise for the prevention and management of cardiotoxicity in cancer survivors. However as this is an emerging and rapidly growing area, there are few guidelines available to guide clinical practice in this setting. Therefore, this online activity will synthesise the current evidence base and provide clinicians with an up to date summary on how to perform evidence-based exercise assessment and prescription for cancer survivors at risk for cardiotoxicity.  

This is a recording of an ESSA webinar presented on 20 September 2023. 

Presented by Dr Stephen Foulkes, AES, AEP

Steve is a Clinical Exercise Physiologist and a Postdoctoral Research Fellow in the Faculty of Nursing, University of Alberta (Canada) and the Sports Cardiology lab at the Baker Heart and Diabetes Institute. Steve has been a practicing AEP since 2015 with an emphasis on cancer survivors and individuals with cardiovascular sdisease, and completed his PhD in 2021 (Deakin University and the Baker Heart and Diabetes Institute) focused on exercise training for the prevention of cancer therapy-induced cardiotoxicity. 

Steve’s research is focused on using exercise testing and training to improve cardiovascular outcomes for individuals undergoing cancer treatment. Steve is interested in how cancer treatments such as chemotherapy affect the heart, blood vessels and muscles, which he studies through advanced exercise testing and imaging methods including cardiopulmonary exercise testing, exercise cardiac MRI and muscle MRI. Steve’s research also investigates how personalised exercise training interventions can be used to prevent the cardiotoxic effects of cancer therapy.

Rates per person

ESSA Member		$33.00
Non-Member		$55.00
ESSA Student Member		$16.50
Student Non-Member		$27.50
ESSA Member PD+		Complimentary
Non-Member PD+		Complimentary

Please see terms & conditions for registration type definitions.

Access to Online Activity

Your online activity will be available in your ESSA learning profile after purchase.  Please click here to access your ESSA learning profile.

Target Audience

Any Accredited Exercise Physiologist

ESSA CPD Points

Successful completion of an assessment, within 60 days is required to earn applicable CPD Points

Registration

Online: After signing into your ESSA profile, select the blue "Register Myself" button below
Manual Form: click here
International Membership Registration (including BASES, CEPA and SESNZ): click here.

Please note:
* Credit card payment is required with online registration.
* If a tax invoice is required for payment to be made, please use the manual form.
* Upon registering to any ESSA professional development, you automatically agree to our terms & conditions.

Disclaimers

All accredited persons, regardless of any professional development completed/ attended must refer to their accreditation’s Scope of Practice/Standards, and only treat/practice within the same.  

ESSA confirms that at the date of release, this professional development meets the requirements of the ESSA Continuing Professional Development Points Guidelines. The information contained in this professional development is of a general nature only, and while every effort and care has been taken to ensure that all representations are accurate as at the date of its release, ESSA accepts no legal liability for any loss or damage suffered as a result of any information provided in this professional development. 

ESSA recommends that its members seek appropriate independent professional advice specific to their particular purposes and circumstances (including the provision of medical advice to patients) before relying on it. 

All professional development listed is correct at time of publication, and is subject to change at any time without notice.